RecruitingNot Applicable

Virtual Biopsy Development to Identify Patient's Glioma Grade at the CHU of Poitiers Using Magnetic Resonance Imaging

France500 participantsStarted 2021-02-22

Plain-language summary

Glioma is a tumor of the central nervous system. These lesions are sorted with the WHO ranking regarding the tumoral oncotype. The tumoral MRI assessment is the first step before any medical decision. Currently, only anatomical biopsy can give the tumor grade definition and help to define the most adapted treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age≥ 18 years, * Patient with suspected glioma with prior imaging * Subject free, with legal protection guardianship or curatorship; * Enrollment in the French Social Security system; * Informed consent signed by the patient Exclusion Criteria: * Any contraindication to an MRI examination * Legal protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons residing in a health or social establishment, adults under legal protection and finally patients in emergency situations * Pregnant or lactating women, women of childbearing age who do not have effective contraception

What they're measuring

Validation of the virtual biopsy in the context of gliomas through the use of statistical learning algorithms (artificial intelligence) compared to the biopsy.

Timeframe: The MRI examination (for 2 hours 30 minutes)

Trial details

NCT IDNCT04313140

SponsorPoitiers University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-02

Contact for this trial

Rémy GUILLEVIN, Pr

05.49.44.45.42 remy.guillevin@chu-poitiers.fr

View on ClinicalTrials.gov More Development of the Virtual Biopsy trials